Literature DB >> 29559429

Trials that say "maybe": the disconnect between exploratory and confirmatory testing after drug approval.

Benjamin Carlisle1, Carole A Federico1, Jonathan Kimmelman2.   

Abstract

Mesh：

Substances：

Year:  2018        PMID： 29559429     DOI： 10.1136/bmj.k959

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  3 in total

1.  Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France.

Authors:  Damien Driot; Emilie Jouanjus; Stéphane Oustric; Julie Dupouy; Maryse Lapeyre-Mestre
Journal:  Br J Clin Pharmacol       Date:  2019-03-28       Impact factor: 4.335

2.  Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort study.

Authors:  Benjamin Gregory Carlisle; Adélaïde Doussau; Jonathan Kimmelman
Journal:  BMJ Open       Date:  2020-02-17       Impact factor: 2.692

3.  Diminishing clinical impact for post-approval cancer clinical trials: A retrospective cohort study.

Authors:  Charlotte Ouimet; Gauthier Bouche; Jonathan Kimmelman
Journal:  PLoS One       Date:  2022-09-12       Impact factor: 3.752
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.